Scienture Holdings, Inc.
SCIENTURE Reports Q3 2026 Results with Approximately 265% Sequential Revenue Growth Driven by the Commercial Launch of REZENOPY™
Q3 2026 Revenue Increased Approximately 113% Year-Over-Year to $1.25 Million
Company newsroom
NASDAQ:SCNX
1 releases
Q3 2026 Revenue Increased Approximately 113% Year-Over-Year to $1.25 Million